Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Por Fury, Matthew G., Baxi, Shrujal, Shen, Ronglai, Kelly, Katherine W., Lipson, Brynna L., Carlson, Diane, Stambuk, Hilda, Haque, Sofia, Pfister, David G.
Publicado em 2011

A Phase II Trial of Bevacizumab + Cetuximab + Cisplatin with Concurrent Intensity Modulated Radiation Therapy (IMRT) for Patients with Stage III/IVB Head and Neck Squamous Cell Car...

Por Fury, Matthew G., Xiao, Han, Sherman, Eric J., Baxi, Shrujal, Smith-Marrone, Stephanie, Schupak, Karen, Gewanter, Richard, Gelblum, Daphna, Haque, Sofia, Schoder, Heiko, Shah, Jatin P., Katabi, Nora, Kurtzman, Rachel, Lipson, Brynna, Cox, Lisa, Lee, Nancy Y., Pfister, David G.
Publicado no Head Neck (2015)

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Por Fury, Matthew G., Sherman, Eric, Lisa, Donna, Agarwal, Neeraj, Algazy, Kenneth, Brockstein, Bruce, Langer, Corey, Lim, Dean, Mehra, Ranee, Rajan, Sandeep K., Korte, Susan, Lipson, Brynna, Yunus, Furhan, Tanvetyanon, Tawee, Smith-Marrone, Stephanie, Ng, Kenneth, Xiao, Han, Haque, Sofia, Pfister, David G.
Publicado no J Natl Compr Canc Netw (2012)